kras g12d inhibitor qtx3046
Generic: KRAS G12D Inhibitor QTX3046
kras g12d inhibitor qtx3046: 1 clinical trial tracked.
kras g12d inhibitor qtx3046 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about kras g12d inhibitor qtx3046, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs)
Interventionalopen240 targetStarted 2024-05Completion 2027-075 sites · United StatesQuanta Therapeutics